ORIC
Neutral signalScored 2026-10-26 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
ORIC Pharmaceuticals, Inc.
- Nom
- ORIC Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.4B
- Employés
- 111
- PDG
- Jacob Chacko
- Site web
- https://www.oricpharma.com
- Marché
- AVBPCRVSELVNJANXMGNXNUVB
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 7 000 titres (~84 140,00 $ US)
- Insiders
- Heyman Richard A.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,476,415
Avg sell (VWAP, 90d window) $13.62 vs last close $8.96 (-34.3%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,287,024 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-07-24
- Liquidity
- Thin $15,488,409/day · 20d vol
- Last synced
-
2026-10-27 00:34:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-20 | Piscitelli Dominic | Sell · S | 14,000 | $13.53 | $189,391 | Form 4 |
| 2026-10-01 | Heyman Richard A. | Sell · S · 10b5-1 | 3,500 | $12.91 | $45,199 | Form 4 |
| 2026-09-28 | Piscitelli Dominic | Sell · S · 10b5-1 | 13,400 | $13.53 | $181,258 | Form 4 |
| 2026-09-24 | Piscitelli Dominic | Sell · S · 10b5-1 | 500 | $13.51 | $6,752 | Form 4 |
| 2026-08-26 | Piscitelli Dominic | Sell · S · 10b5-1 | 77,000 | $13.69 | $1,053,814 | Form 4 |
| 2026-07-24 | Heyman Richard A. | Sell · S · 10b5-1 | 7,000 | $12.02 | $84,140 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-26 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
ORIC presents a compelling clinical catalyst with enozertinib's 84-88% response rates in EGFR atypical NSCLC and a planned Phase 3 advancement, supported by a strong liquidity runway (score 85) that reduces near-term…
The first sentence of the analysis written for ORIC on 2026-10-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $84K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $84K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 14.13 · operating margin 0.0%
Suggested stop 7.67, nearest stored support minus 0.5 ATR(14.4% under the last close). Reward/risk to the next stored resistance is 2.91. Research, not advice. Not an order.
Recent news
- 2026-10-23 ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
- 2026-10-23 Oric Pharmaceuticals'' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study Oric Pharmaceuticals NASDAQ: ORIC reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations, highlighting systemic and intracranial responses in a cohort with a high prevalence of baseline brain metastases.
- 2026-10-23 ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses
- 2026-10-23 ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness
- 2026-10-19 ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations SOUTH SAN FRANCISCO, Calif.
- 2026-10-05 ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced an agreement with Cancer Research UK, one of the world''s largest funders of cancer research, to advance a potential first-in-class CIP2A-targeted therapy into clinical development.
- 2026-10-02 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026.
- 2026-09-16 ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-04 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.
- 2026-09-02 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September:
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 14.129 | 10.555 | 10.392 | 13.677 | 15.875 | |
| Quick Ratio | 14.129 | 10.555 | 10.392 | 13.677 | 15.875 | |
| Solvency Ratio | -4.814 | -4.086 | -3.257 | -3.148 | -3.032 | |
| Cash Ratio | 2.237 | 2.391 | 1.143 | 4.344 | 14.917 | |
| Price To Earnings Ratio | -5.565 | -4.410 | -4.694 | -2.618 | -7.101 | |
| Price To Earnings Growth Ratio | 0.283 | 0.665 | 0.364 | -0.301 | 0.185 | |
| Forward Price To Earnings Growth Ratio | 0.283 | 0.665 | 0.364 | -0.301 | 0.185 | |
| Price To Earnings Diluted Ratio | -5.565 | -4.410 | -4.694 | -2.618 | -7.101 | |
| Price To Earnings Diluted Growth Ratio | 0.283 | 0.665 | 0.364 | -0.301 | 0.185 | |
| Price To Book Ratio | 1.868 | 2.314 | 2.112 | 1.050 | 2.044 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -6.295 | -4.942 | -5.470 | -3.025 | -9.225 | |
| Price To Operating Cash Flow Ratio | -6.335 | -4.995 | -5.524 | -3.108 | -9.370 | |
| Debt To Assets Ratio | 0.028 | 0.012 | 0.040 | 0.048 | 0.006 | |
| Debt To Equity Ratio | 0.030 | 0.013 | 0.046 | 0.054 | 0.007 | |
| Debt To Capital Ratio | 0.029 | 0.013 | 0.044 | 0.052 | 0.007 | |
| Long Term Debt To Capital Ratio | 0.011 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.069 | 1.128 | 1.137 | 1.126 | 1.094 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -5.553 | -4.534 | -4.188 | -4.883 | -3.930 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | 1.011 | 1.010 | 1.028 | 1.016 | |
| Debt Service Coverage Ratio | -38.513 | 0.000 | -36.215 | -16.177 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -34.695 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -34.044 | 0.000 | -31.137 | -28.260 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -9.814 | -35.395 | -8.390 | -6.211 | -30.914 | |
| Capital Expenditure Coverage Ratio | -159.223 | -94.833 | -100.928 | -36.161 | -63.409 | |
| Dividend Paid And Capex Coverage Ratio | -159.223 | -94.833 | -100.928 | -36.161 | -63.409 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.334 | -3.996 | -4.617 | -2.084 | -4.290 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 14.129 | ▲3.574 | ▲1.203 |
| Quick Ratio | 14.129 | ▲3.574 | ▲1.203 |
| Solvency Ratio | -4.814 | ▼-0.728 | ▼-1.147 |
| Cash Ratio | 2.237 | ▼-0.154 | ▼-2.769 |
| Price To Earnings Ratio | -5.565 | ▼-1.155 | ▼-0.687 |
| Price To Earnings Growth Ratio | 0.283 | ▼-0.382 | ▲0.044 |
| Forward Price To Earnings Growth Ratio | 0.283 | ▼-0.382 | ▲0.044 |
| Price To Earnings Diluted Ratio | -5.565 | ▼-1.155 | ▼-0.687 |
| Price To Earnings Diluted Growth Ratio | 0.283 | ▼-0.382 | ▲0.044 |
| Price To Book Ratio | 1.868 | ▼-0.446 | ▼-0.009 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -6.295 | ▼-1.353 | ▼-0.504 |
| Price To Operating Cash Flow Ratio | -6.335 | ▼-1.340 | ▼-0.468 |
| Debt To Assets Ratio | 0.028 | ▲0.017 | ▲0.001 |
| Debt To Equity Ratio | 0.030 | ▲0.017 | 0.000 |
| Debt To Capital Ratio | 0.029 | ▲0.016 | ▲0.000 |
| Long Term Debt To Capital Ratio | 0.011 | ▲0.011 | ▲0.009 |
| Financial Leverage Ratio | 1.069 | ▼-0.058 | ▼-0.041 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -5.553 | ▼-1.018 | ▼-0.935 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | ▼-0.004 | ▼-0.008 |
| Debt Service Coverage Ratio | -38.513 | ▼-38.513 | ▼-20.332 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲6.939 |
| Short Term Operating Cash Flow Coverage Ratio | -34.044 | ▼-34.044 | ▼-15.356 |
| Operating Cash Flow Coverage Ratio | -9.814 | ▲25.581 | ▲8.331 |
| Capital Expenditure Coverage Ratio | -159.223 | ▼-64.390 | ▼-68.312 |
| Dividend Paid And Capex Coverage Ratio | -159.223 | ▼-64.390 | ▼-68.312 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.334 | ▼-1.337 | ▼-1.269 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $718.2M | $562.7M | $473.3M | $233.6M | $557.9M | |
| Enterprise value | $684.0M | $506.5M | $460.2M | $178.8M | $333.8M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -6.03x | -4.50x | -5.37x | -2.38x | -5.61x | |
| EV / Free cash flow | -6.00x | -4.45x | -5.32x | -2.32x | -5.52x | |
| EV / EBITDA | -5.33x | -4.00x | -4.62x | -2.08x | -4.29x | |
| Net debt / EBITDA | 0.27x | 0.44x | 0.13x | 0.64x | 2.88x | |
| Current ratio | 14.13x | 10.55x | 10.39x | 13.68x | 15.88x | |
| Income quality | 0.88x | 0.88x | 0.85x | 0.84x | 0.76x | |
| Graham net-net | $3 | $3 | $3 | $4 | $6 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 102.7% | 100.0% | |
| Working capital | $268.0M | $237.4M | $192.1M | $195.1M | $225.4M | |
| Invested capital | $277.1M | $240.3M | $204.1M | $209.3M | $227.8M | |
| Return on assets | -31.5% | -46.6% | -39.5% | -35.6% | -26.4% | |
| Operating ROA | -41.7% | -54.0% | -43.9% | -33.4% | -26.4% | |
| Return on tangible assets | -31.5% | -46.6% | -39.5% | -35.6% | -26.4% | |
| Return on equity | -33.7% | -52.6% | -44.9% | -40.1% | -28.8% | |
| Return on invested capital | -36.3% | -56.6% | -46.7% | -38.6% | -27.6% | |
| Return on capital employed | -36.6% | -57.3% | -47.3% | -39.1% | -27.8% | |
| Earnings yield | -18.0% | -22.7% | -21.3% | -38.2% | -14.1% | |
| Free cash flow yield | -15.9% | -20.2% | -18.3% | -33.1% | -10.8% | |
| Capex / Op. cash flow | -0.6% | -1.1% | -1.0% | -2.8% | -1.6% | |
| Capex / Depreciation | 58.4% | 107.3% | 82.3% | 215.1% | 104.7% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 1144d | 510d | 334d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -1144d | -510d | -334d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years